2017
DOI: 10.1016/j.jdcr.2017.01.012
|View full text |Cite
|
Sign up to set email alerts
|

Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0
2

Year Published

2017
2017
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 6 publications
0
6
0
2
Order By: Relevance
“…Given vedolizumab’s gastrointestinal selectivity, and poor activity on skin epithelial inflammatory pathways, we hypothesize that patients who were previously well controlled on biologic drugs with broader selectivity (eg, TNF-α inhibitors) may see flares and intractable cutaneous Crohn’s disease symptoms with vedolizumab. Just as our patient saw exacerbation of her EI/NV with transition of vedolizumab from a TNF-α antagonist, Yeh and Tsiaras 5 reported a case of worsening pyoderma gangrenosum after the initiation of vedolizumab in a patient with Crohn’s disease. These cases serve as examples that although vedolizumab is effective for treating moderate to severe inflammatory bowel disease, initiation of the drug may conversely exacerbate, or inadequately treat, cutaneous symptoms.…”
Section: Discussionmentioning
confidence: 74%
“…Given vedolizumab’s gastrointestinal selectivity, and poor activity on skin epithelial inflammatory pathways, we hypothesize that patients who were previously well controlled on biologic drugs with broader selectivity (eg, TNF-α inhibitors) may see flares and intractable cutaneous Crohn’s disease symptoms with vedolizumab. Just as our patient saw exacerbation of her EI/NV with transition of vedolizumab from a TNF-α antagonist, Yeh and Tsiaras 5 reported a case of worsening pyoderma gangrenosum after the initiation of vedolizumab in a patient with Crohn’s disease. These cases serve as examples that although vedolizumab is effective for treating moderate to severe inflammatory bowel disease, initiation of the drug may conversely exacerbate, or inadequately treat, cutaneous symptoms.…”
Section: Discussionmentioning
confidence: 74%
“…Biological drugs, such as infliximab, adalimumab, vedolizumab, and ustekinumab, are increasingly used in the treatment of non-specific IBD [67][68][69].…”
Section: Biological Drugsmentioning
confidence: 99%
“…W leczeniu NZJ coraz częściej wykorzystywane są leki biologiczne, takie jak infliksymab, adalimumab, wedolizumab i ustekinumab [67][68][69].…”
Section: Leki Biologiczneunclassified
See 2 more Smart Citations